Compare MBI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | ADAG |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 260.3M |
| IPO Year | 1994 | 2020 |
| Metric | MBI | ADAG |
|---|---|---|
| Price | $4.47 | $3.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 471.3K | 185.6K |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.48 | N/A |
| 52 Week Low | $4.53 | $1.44 |
| 52 Week High | $8.17 | $4.85 |
| Indicator | MBI | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 31.11 | 29.87 |
| Support Level | N/A | $2.78 |
| Resistance Level | $6.22 | $3.19 |
| Average True Range (ATR) | 0.14 | 0.27 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 10.40 | 3.86 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. The U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiaries.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.